GI Innovation is a bio venture company focused on the research and development of innovative protein-based drugs. The company operates in the biotechnology sector, serving patients worldwide by creating new bio drugs through structured translational research. GI Innovation leverages its proprietary platform, which includes high throughput screening systems and bispecific antibody programs, to efficiently discover and develop lead products and cell lines. The company primarily targets the global healthcare market, aiming to address unmet medical needs with its novel therapeutic solutions. Its business model revolves around the development and commercialization of patented substances, ensuring exclusive rights to their innovative drugs. Revenue is generated through the sale of these proprietary drugs and potential licensing agreements with other pharmaceutical companies. Key clients include healthcare providers, research institutions, and pharmaceutical companies looking for cutting-edge bio drug solutions.

Keywords: biotechnology, protein-based drugs, translational research, high throughput screening, bispecific antibodies, global healthcare, innovative therapeutics, patented substances, commercialization, pharmaceutical partnerships.